Acetate

metabolite

Elevated acetate reflects myocardial Krebs-cycle impairment during ischemia-reperfusion injury.

Pathway placement

Cascade stepOff-pathway / systemic markers

Confidencemedium

RationaleReflects impaired Krebs cycle and myocardial energy metabolism in ischemia-reperfusion.

Also acts inMyocardial injury

Druggability

Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresType-II-associated

R — rupture / Type-I

—

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)-35

Confounder panel (Type-II drivers)

1sepsis / systemic inflammationmag 2

2anemia / acute blood lossn/a

3hypovolemia / dehydrationn/a

4tachyarrhythmian/a

5hypoxemia / respiratory failuremag 1

6hypertensive emergencyn/a

7high-demand / peri-operative stressn/a

Coverage: 2/7 confounders with evidence

Tier: deep-scored (abstract-extracted) · 4 supporting references. See the discrimination table for all markers.

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Serum, plasma or urine

Collection tube

Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container

Method / principle

LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available

Reagent / substrate

Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent

Platform

LC-MS/MS; some automated chemistry

Turnaround · availability

Send-out / research · Specialized / research

CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2)
NCT00211939 · PHASE4 · COMPLETED · calcium acetate, sevelamer, atorvastatin